A draft guidance issued by the National Institute for Health and Care Excellence (NICE), a U.K. advisory board, and a review by England’s National Health Service (NHS) call for more research into medical cannabis for multiple sclerosis and other conditions.
The board’s fast-tracked guidance on cannabis-based medicinal products, open for public consultation until Sept. 5 and set to be published on Nov. 4, follows last year’s re-classification of these products to enable their use by patients whose clinical needs cannot be met by approved medications.
The assessment looked at the clinical- and cost-effectiveness of most cannabis-based products, including Sativex (by GW Pharmaceuticals). Therapies for intractable nausea and vomiting due to chemotherapy, chronic pain, and treatment-resistant severe epilepsy were also considered.
Eight separate recommendations for further research were